Orexigen Therapeutic (OREX) 3.35 $OREX
Orexigen Completes Acquisition of All U.S. Rights to Contrave® and Launches U.S. Sales Organization
PR Newswire - 37 mins ago
Orexigen Therapeutics (NASDAQ: OREX) announced today that it has successfully completed its previously announced acquisition of the United States rights to Contrave® (naltrexone HCl/bupropion HCl extended release) and relaunched Contrave with the Company's own sales organization. The acquisition was originally announced March 2016 and was completed two months ahead of schedule.
OREX: 3.35 (-0.03)
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Laboratorios FarmaceÌuticos Rovi, S.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Spain
PR Newswire - 38 mins ago
Orexigen Therapeutics, Inc. (NASDAQ:OREX) today announced that wholly owned subsidiary Orexigen Therapeutics Ireland Ltd. and Laboratorios FarmaceÌuticos Rovi, S.A. (ROVI) have executed a commercialization and distributorship agreement for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Spain. Mysimba is approved by the European Medicines Agency for the management of weight in adult patients (greater-than or equal to 18 years) with an initial Body Mass Index (BMI) of greater-than or equal to 30 kg/m2 (obese), or greater-than or equal to 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension). Founded in 1946 and headquartered in Madrid, Spain, ROVI has a diversified pharmaceutical portfolio.
OREX: 3.35 (-0.03)
Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Wed Jun 22, 3:30PM CDT
Orexigen Therapeutics, Inc. (NASDAQ: OREX) announced today that the Compensation Committee of the Company's Board of Directors has approved the grant of inducement stock options to purchase a total of 232,500 shares of common stock to six new employees. Additionally, the Compensation Committee approved two individually negotiated inducement stock option grants, including options to purchase 225,000 shares of common stock to Salma Jutt-Eghbali, Head of Commercial Innovation, and options to purchase 45,000 shares of common stock to Kim Burns, National Account Executive.
OREX: 3.35 (-0.03)
Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.35 (-0.03), RTRX: 17.93 (+0.40), VVUS: 1.07 (+0.01), ARNA: 1.67 (-0.01)
Orexigen Therapeutics Announces Promotions of Tom Cannell to COO and Jason Keyes to CFO
PR Newswire - Wed Jun 08, 3:10PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the promotions of Thomas Cannell, D.V.M., to Executive Vice President, Chief Operating Officer, and President of Global Commercial Products and Jason Keyes to Senior Vice President, Chief Financial Officer.
OREX: 3.35 (-0.03)
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave® Patent Litigation
PR Newswire - Wed Jun 08, 8:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the United States District Court for the District of Delaware has issued a claim construction (Markman) ruling governing patent litigation brought by Orexigen and Takeda Pharmaceuticals against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis Pharma, Inc., and Actavis Inc., collectively referred to as Actavis. The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell a generic version of the currently approved dose of Contrave® (naltrexone HCl / bupropion HCl extended release) tablets prior to the expiration of U.S. Patents listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. There are 10 Contrave patents listed in the Orange Book, the last of which expires in 2032.
OREX: 3.35 (-0.03)
Orexigen Announces Upcoming Presentations at European Obesity Summit 2016
PR Newswire - Fri May 27, 3:10PM CDT
Orexigen Therapeutics (NASDAQ: OREX) announced today six poster presentations, including two selected as poster pitch sessions, on naltrexone HCl / bupropion HCl, marketed as Contrave® in the United States and Mysimba® in the European Union, at the European Obesity Summit 2016 at The Swedish Exhibition and Congress Centre in Gothenburg, Sweden on June 1-4, 2016.
OREX: 3.35 (-0.03)
Orexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from Board
PR Newswire - Fri May 27, 8:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Orexigen co-founder and former Chairman, Eckard Weber, M.D., has resigned from the Board of Directors. Dr. Weber served as Chairman from 2002 until earlier this year. From November 2008 until March 2009, Dr. Weber also served as interim President and Chief Executive Officer.
OREX: 3.35 (-0.03)
Orexigen Appoints New Member of Board of Directors and Announces Senior Management Changes
PR Newswire - Mon May 23, 7:30AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the appointment of Deborah A. Jorn to its Board of Directors, effective immediately. The Company also announced Dr. Preston Klassen has resigned to pursue other interests in drug development with a private company. Peter Flynn, PhD has been appointed as Senior Vice President, Head of Development, Regulatory Affairs and Safety, while Toni Foster will continue in her role as Senior Vice President, Project Management Office and Clinical Operations.
OREX: 3.35 (-0.03), JNJ: 125.23 (+0.77)
Orexigen reports 1Q loss
Automated Insights - Wed May 04, 3:51PM CDT
LA JOLLA, Calif. (AP) _ Orexigen Therapeutics Inc. (OREX) on Wednesday reported a loss of $22.3 million in its first quarter.
OREX: 3.35 (-0.03)
Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016
PR Newswire - Wed May 04, 3:01PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the first quarter ended March 31, 2016.
OREX: 3.35 (-0.03)
Orexigen Therapeutics to Speak at the Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Tue May 03, 4:30PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas. The discussion is scheduled for Tuesday, May 10th, at 1:00 p.m. Pacific Time.
OREX: 3.35 (-0.03)
Orexigen Expands Commercial Leadership Team with Appointment of Healthcare Industry Veteran Brian Longstreet as Senior Vice President of Global Market Access and Development
PR Newswire - Tue May 03, 7:30AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the appointment of Brian Longstreet as Senior Vice President of Global Market Access and Development. In this new role, Longstreet will be responsible for leading Orexigen's market access and development strategy, relationships and execution. In March 2016, Orexigen announced the agreement to acquire full United States rights to Contrave® (naltrexone HCI and bupropion HCI extended release) following a six month transition period. Orexigen is preparing to assume U.S. commercialization of the product later this year. The Company has now hired the commercial leadership team to launch an effective and efficient U.S. sales and marketing organization to drive the next phase of growth for Contrave.
OREX: 3.35 (-0.03), MRK: 58.66 (+0.23)
Orexigen Announces South Korean Approval of Contrave® (naltrexone HCI and bupropion HCI Extended-Release) Monotherapy for Weight Management in Overweight or Obese Adult Patients
PR Newswire - Mon May 02, 7:30AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the Korean Ministry of Food and Drug Safety (MFDS) has approved Contrave® (naltrexone HCI and bupropion HCI extended release) monotherapy for weight management in overweight or obese adult patients. In anticipation of a commercial launch this quarter, Orexigen has shipped an initial order of Contrave tablets to Kwang Dong Pharmaceutical Company, Ltd., the Company's partner for South Korea. This shipment and a subsequent firm order from Kwang Dong for later in 2016 have a combined value to Orexigen of approximately $5.9 million.
OREX: 3.35 (-0.03)
Orexigen Announces Upcoming Presentations at XIII International Congress on Obesity hosted by the World Obesity Federation
PR Newswire - Thu Apr 28, 8:00AM CDT
Orexigen Therapeutics (NASDAQ: OREX) announced today upcoming oral and poster presentations on naltrexone HCl / bupropion HCl, marketed as Contrave® in the United States and Mysimba® in Europe, at the XIII International Congress on Obesity (ICO) at the Vancouver Convention Center in Vancouver, Canada on May 1-4, 2016.
OREX: 3.35 (-0.03)
Penny Stocks To Watch: Four Top Small Cap Stocks on Monday April 25
ACCESSWIRE - Mon Apr 25, 11:44AM CDT
MIAMI, FL / ACCESSWIRE / April 25, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. TLOG, LPTN, OREX, and BTUUQ have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
OREX: 3.35 (-0.03), LPTN: 1.95 (-0.05), TLOG: 0.23 (unch)
Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth Eastland, Vice President of Sales, and Eight Additional New Employees
PR Newswire - Mon Apr 25, 8:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the appointment of Beth Eastland as Vice President of Sales and eight other additional new employees. In March 2016, Orexigen acquired full United States rights to Contrave® (naltrexone HCI and bupropion HCI), and the company is preparing to assume United States commercialization of the product later this year. Orexigen is launching an efficient U.S. commercial organization to execute a targeted, data-driven sales and marketing plan to drive the next phase of growth for Contrave.
OREX: 3.35 (-0.03)
The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen
MDVN: 63.99 (+1.50), OREX: 3.35 (-0.03), SNTA: 0.34 (+0.07), GILD: 79.47 (-1.77), ABBV: 66.23 (+1.51)
Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2016 Financial Results on May 4, 2016
PR Newswire - Wed Apr 20, 4:00PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce corporate and financial results for the first quarter 2016 on Wednesday, May 4th after the market closes. Following the announcement, Orexigen will provide a business update and discuss the financial results in a live webcast and conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).
OREX: 3.35 (-0.03)
Orexigen Completes Acquisition of All U.S. Rights to Contrave® and Launches U.S. Sales Organization
PR Newswire - 37 mins ago
Orexigen Therapeutics (NASDAQ: OREX) announced today that it has successfully completed its previously announced acquisition of the United States rights to Contrave® (naltrexone HCl/bupropion HCl extended release) and relaunched Contrave with the Company's own sales organization. The acquisition was originally announced March 2016 and was completed two months ahead of schedule.
OREX: 3.35 (-0.03)
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Laboratorios FarmaceÌuticos Rovi, S.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Spain
PR Newswire - 38 mins ago
Orexigen Therapeutics, Inc. (NASDAQ:OREX) today announced that wholly owned subsidiary Orexigen Therapeutics Ireland Ltd. and Laboratorios FarmaceÌuticos Rovi, S.A. (ROVI) have executed a commercialization and distributorship agreement for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Spain. Mysimba is approved by the European Medicines Agency for the management of weight in adult patients (greater-than or equal to 18 years) with an initial Body Mass Index (BMI) of greater-than or equal to 30 kg/m2 (obese), or greater-than or equal to 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension). Founded in 1946 and headquartered in Madrid, Spain, ROVI has a diversified pharmaceutical portfolio.
OREX: 3.35 (-0.03)
Orexigen Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
PR Newswire - Wed Jun 22, 3:30PM CDT
Orexigen Therapeutics, Inc. (NASDAQ: OREX) announced today that the Compensation Committee of the Company's Board of Directors has approved the grant of inducement stock options to purchase a total of 232,500 shares of common stock to six new employees. Additionally, the Compensation Committee approved two individually negotiated inducement stock option grants, including options to purchase 225,000 shares of common stock to Salma Jutt-Eghbali, Head of Commercial Innovation, and options to purchase 45,000 shares of common stock to Kim Burns, National Account Executive.
OREX: 3.35 (-0.03)
Orexigen Stock Gains More than 50% on Markman Hearing
Arpita Dutt - Zacks Investment Research - Thu Jun 09, 7:58AM CDT
Orexigen's (OREX) shares shot up on a favorable Markman hearing in the Contrave patent infringement lawsuit.
OREX: 3.35 (-0.03), RTRX: 17.93 (+0.40), VVUS: 1.07 (+0.01), ARNA: 1.67 (-0.01)
Orexigen Therapeutics Announces Promotions of Tom Cannell to COO and Jason Keyes to CFO
PR Newswire - Wed Jun 08, 3:10PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the promotions of Thomas Cannell, D.V.M., to Executive Vice President, Chief Operating Officer, and President of Global Commercial Products and Jason Keyes to Senior Vice President, Chief Financial Officer.
OREX: 3.35 (-0.03)
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave® Patent Litigation
PR Newswire - Wed Jun 08, 8:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the United States District Court for the District of Delaware has issued a claim construction (Markman) ruling governing patent litigation brought by Orexigen and Takeda Pharmaceuticals against Actavis Laboratories FL, Inc., Andrx Corporation, Actavis Pharma, Inc., and Actavis Inc., collectively referred to as Actavis. The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell a generic version of the currently approved dose of Contrave® (naltrexone HCl / bupropion HCl extended release) tablets prior to the expiration of U.S. Patents listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. There are 10 Contrave patents listed in the Orange Book, the last of which expires in 2032.
OREX: 3.35 (-0.03)
Orexigen Announces Upcoming Presentations at European Obesity Summit 2016
PR Newswire - Fri May 27, 3:10PM CDT
Orexigen Therapeutics (NASDAQ: OREX) announced today six poster presentations, including two selected as poster pitch sessions, on naltrexone HCl / bupropion HCl, marketed as Contrave® in the United States and Mysimba® in the European Union, at the European Obesity Summit 2016 at The Swedish Exhibition and Congress Centre in Gothenburg, Sweden on June 1-4, 2016.
OREX: 3.35 (-0.03)
Orexigen Therapeutics Founder and Former Chairman Eckard Weber Steps Down from Board
PR Newswire - Fri May 27, 8:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that Orexigen co-founder and former Chairman, Eckard Weber, M.D., has resigned from the Board of Directors. Dr. Weber served as Chairman from 2002 until earlier this year. From November 2008 until March 2009, Dr. Weber also served as interim President and Chief Executive Officer.
OREX: 3.35 (-0.03)
Orexigen Appoints New Member of Board of Directors and Announces Senior Management Changes
PR Newswire - Mon May 23, 7:30AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the appointment of Deborah A. Jorn to its Board of Directors, effective immediately. The Company also announced Dr. Preston Klassen has resigned to pursue other interests in drug development with a private company. Peter Flynn, PhD has been appointed as Senior Vice President, Head of Development, Regulatory Affairs and Safety, while Toni Foster will continue in her role as Senior Vice President, Project Management Office and Clinical Operations.
OREX: 3.35 (-0.03), JNJ: 125.23 (+0.77)
Orexigen reports 1Q loss
Automated Insights - Wed May 04, 3:51PM CDT
LA JOLLA, Calif. (AP) _ Orexigen Therapeutics Inc. (OREX) on Wednesday reported a loss of $22.3 million in its first quarter.
OREX: 3.35 (-0.03)
Orexigen Therapeutics Reports Business and Financial Results for the First Quarter Ended March 31, 2016
PR Newswire - Wed May 04, 3:01PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the first quarter ended March 31, 2016.
OREX: 3.35 (-0.03)
Orexigen Therapeutics to Speak at the Bank of America Merrill Lynch 2016 Health Care Conference
PR Newswire - Tue May 03, 4:30PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas. The discussion is scheduled for Tuesday, May 10th, at 1:00 p.m. Pacific Time.
OREX: 3.35 (-0.03)
Orexigen Expands Commercial Leadership Team with Appointment of Healthcare Industry Veteran Brian Longstreet as Senior Vice President of Global Market Access and Development
PR Newswire - Tue May 03, 7:30AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the appointment of Brian Longstreet as Senior Vice President of Global Market Access and Development. In this new role, Longstreet will be responsible for leading Orexigen's market access and development strategy, relationships and execution. In March 2016, Orexigen announced the agreement to acquire full United States rights to Contrave® (naltrexone HCI and bupropion HCI extended release) following a six month transition period. Orexigen is preparing to assume U.S. commercialization of the product later this year. The Company has now hired the commercial leadership team to launch an effective and efficient U.S. sales and marketing organization to drive the next phase of growth for Contrave.
OREX: 3.35 (-0.03), MRK: 58.66 (+0.23)
Orexigen Announces South Korean Approval of Contrave® (naltrexone HCI and bupropion HCI Extended-Release) Monotherapy for Weight Management in Overweight or Obese Adult Patients
PR Newswire - Mon May 02, 7:30AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the Korean Ministry of Food and Drug Safety (MFDS) has approved Contrave® (naltrexone HCI and bupropion HCI extended release) monotherapy for weight management in overweight or obese adult patients. In anticipation of a commercial launch this quarter, Orexigen has shipped an initial order of Contrave tablets to Kwang Dong Pharmaceutical Company, Ltd., the Company's partner for South Korea. This shipment and a subsequent firm order from Kwang Dong for later in 2016 have a combined value to Orexigen of approximately $5.9 million.
OREX: 3.35 (-0.03)
Orexigen Announces Upcoming Presentations at XIII International Congress on Obesity hosted by the World Obesity Federation
PR Newswire - Thu Apr 28, 8:00AM CDT
Orexigen Therapeutics (NASDAQ: OREX) announced today upcoming oral and poster presentations on naltrexone HCl / bupropion HCl, marketed as Contrave® in the United States and Mysimba® in Europe, at the XIII International Congress on Obesity (ICO) at the Vancouver Convention Center in Vancouver, Canada on May 1-4, 2016.
OREX: 3.35 (-0.03)
Penny Stocks To Watch: Four Top Small Cap Stocks on Monday April 25
ACCESSWIRE - Mon Apr 25, 11:44AM CDT
MIAMI, FL / ACCESSWIRE / April 25, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. TLOG, LPTN, OREX, and BTUUQ have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.
OREX: 3.35 (-0.03), LPTN: 1.95 (-0.05), TLOG: 0.23 (unch)
Orexigen Therapeutics Expands Commercial Capabilities with Appointment of Beth Eastland, Vice President of Sales, and Eight Additional New Employees
PR Newswire - Mon Apr 25, 8:00AM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced the appointment of Beth Eastland as Vice President of Sales and eight other additional new employees. In March 2016, Orexigen acquired full United States rights to Contrave® (naltrexone HCI and bupropion HCI), and the company is preparing to assume United States commercialization of the product later this year. Orexigen is launching an efficient U.S. commercial organization to execute a targeted, data-driven sales and marketing plan to drive the next phase of growth for Contrave.
OREX: 3.35 (-0.03)
The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen
Zacks Equity Research - Zacks Investment Research - Thu Apr 21, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen
MDVN: 63.99 (+1.50), OREX: 3.35 (-0.03), SNTA: 0.34 (+0.07), GILD: 79.47 (-1.77), ABBV: 66.23 (+1.51)
Orexigen Therapeutics to Provide Business Update and Discuss First Quarter 2016 Financial Results on May 4, 2016
PR Newswire - Wed Apr 20, 4:00PM CDT
Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce corporate and financial results for the first quarter 2016 on Wednesday, May 4th after the market closes. Following the announcement, Orexigen will provide a business update and discuss the financial results in a live webcast and conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).
OREX: 3.35 (-0.03)
